Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Pre-treatment polyfunctionality percentage (PFA) of CD8+ T cells is associated with development of immune-related adverse events (irAEs) in patients receiving immune checkpoint inhibitors (ICIs). Local targets link to admitted publications; unresolved targets remain external evidence.
Five-year survival with combined Nivolumab and Ipilimumab in advanced melanoma
10.1056/nejmoa1910836 · 2019 · External reference
Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score ≥ 50
10.1200/jco.21.00174 · 2021 · External reference
Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer
10.1200/jco.21.01308 · 2022 · External reference
Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial
10.1016/s0140-6736(25)00403-9 · 2025 · External reference
Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis
10.1001/jamaoncol.2019.0393 · 2019 · External reference
Biomarkers associated with immune-related adverse events induced by immune checkpoint inhibitors
10.5306/wjco.v15.i8.1002 · 2024 · External reference
Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma
10.1186/s40425-015-0081-1 · 2015 · External reference
Immune dysregulation in cancer patients developing immune-related adverse events
10.1038/s41416-018-0155-1 · 2019 · External reference
Circulating cytokines predict immune-related toxicity in melanoma patients receiving Anti-PD-1-based immunotherapy
10.1158/1078-0432.ccr-18-2795 · 2019 · External reference
Differential impact of magnitude, polyfunctional capacity, and specificity of HIV-specific CD8+ T cell responses on HIV set point
10.1128/jvi.02968-13 · 2014 · External reference
Polyfunctional T cell responses are a hallmark of HIV-2 infection
10.1002/eji.200737768 · 2008 · External reference
A clinical microchip for evaluation of single immune cells reveals high functional heterogeneity in phenotypically similar T cells
10.1038/nm.2375 · 2011 · External reference
Multifunctional T-cell analyses to study response and progression in adoptive cell transfer immunotherapy
10.1158/2159-8290.cd-12-0383 · 2013 · External reference
Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL
10.1182/blood-2018-01-828343 · 2018 · External reference
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
10.1016/j.ejca.2008.10.026 · 2009 · External reference
10.1056/nejmoa1801005
10.1056/nejmoa1801005 · External reference
